Completed PHASE1 INTERVENTIONAL 4-arm NCT02169466

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Sponsor: Bial - Portela C S.A.

Conditions Parkinson's Disease (PD)

Interventions BIA 9-1067 Madopar® HBS Placebo

Updated 8 times since 2017 Last updated: Oct 2, 2015 Started: Jan 31, 2009 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Parkinson's Disease (PD), this trial is completed. The trial is conducted by Bial - Portela C S.A. and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bial - Portela C S.A.

Data source: Bial - Portela C S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• S. Mamede Do Coronado, Portugal